When Otsuka's patent on aripiprazole approached its end, the company developed and marketed brexpiprazole (Rexulti) — a closely related partial dopamine agonist with a deliberately tweaked receptor profile. The goal was to reduce two of aripiprazole's most common complaints: akathisia and insomnia. Whether brexpiprazole achieves that is one of the more interesting subtle comparisons in modern psychopharmacology.
Brexpiprazole shares aripiprazole's dopamine partial-agonist mechanism but has lower intrinsic D2 activity and stronger 5-HT1A and 5-HT2A binding — generally producing fewer activation side effects but somewhat less of aripiprazole's "energising" profile.
The pharmacological tweak
Both drugs act as partial agonists at the dopamine D2 receptor — meaning they activate it less than dopamine itself does, providing a kind of dimmer switch. The key differences:
- Brexpiprazole has lower intrinsic activity at D2 — it activates the receptor less than aripiprazole does. This is the leading explanation for its lower akathisia rate.
- Brexpiprazole has higher affinity at 5-HT1A and 5-HT2A serotonin receptors — which may contribute to its anxiolytic and antidepressant effects.
- Brexpiprazole has less intrinsic activity at the D3 receptor — possibly relevant to differences in impulse-control side effects, though both drugs carry the same FDA label warning.
What's approved
Aripiprazole has a broader set of FDA indications: schizophrenia, bipolar I, adjunctive treatment of major depressive disorder (MDD), irritability in autism, and Tourette's. Brexpiprazole is approved for schizophrenia, adjunctive treatment of MDD, and (since 2023) agitation associated with dementia related to Alzheimer's disease — a significant first-in-class approval.
Efficacy: comparable
No head-to-head efficacy trials of aripiprazole vs brexpiprazole in schizophrenia have been published. Network meta-analyses place them at very similar efficacy levels for positive symptoms — middle of the pack among atypicals, behind clozapine and olanzapine but well ahead of placebo. For adjunctive treatment of MDD, both show modest but real benefit when added to an SSRI or SNRI.
Tolerability: where the differences appear
Akathisia and activation
This is brexpiprazole's strongest claim. In pivotal trials and post-marketing surveillance, akathisia rates for brexpiprazole are generally lower than for aripiprazole — though still higher than placebo. Patients who developed intolerable akathisia on aripiprazole often (not always) tolerate brexpiprazole better. Insomnia and a "wired" feeling are also reported less often.
Weight
Brexpiprazole tends to cause slightly more weight gain than aripiprazole — around 1–3 kg over 6 months in most studies, compared with aripiprazole's typically smaller average. Neither approaches the weight burden of olanzapine or quetiapine.
Sedation
Brexpiprazole is more sedating than aripiprazole on average, which fits with its slightly different receptor profile. Some patients welcome this; others don't.
Impulse-control behaviours
The FDA's 2016 communication on impulse-control problems (gambling, hypersexuality, binge eating, compulsive shopping) applies to both drugs. Reports suggest the rate may be lower with brexpiprazole, but the warning remains and clinicians should ask about these behaviours regardless of which drug is used.
Prolactin and movement
Both drugs have minimal effects on prolactin and low rates of extrapyramidal symptoms — strong points relative to risperidone or older agents.
The dementia approval
Brexpiprazole is the only antipsychotic with a specific FDA approval for agitation in Alzheimer's disease. The approval came with a boxed warning about increased mortality in elderly patients with dementia-related psychosis (a class warning that applies to all antipsychotics), but the trials supporting approval (e.g., Lee et al., JAMA Neurology) showed modest reductions in agitation. This is meaningful for families and clinicians dealing with severe dementia-related agitation, where treatment options are scarce and difficult.
Cost and availability
Aripiprazole is available as a generic and is relatively inexpensive. Brexpiprazole is brand-only and substantially more expensive. For uninsured or under-insured patients, this often dominates the choice.
Who might prefer aripiprazole
- Cost is a major factor
- The patient values activation (energising effect) over calmness
- Long-acting injectable is needed (Aripiprazole has Maintena and Aristada; brexpiprazole has no LAI)
- Treatment of childhood/adolescent indications (autism irritability, Tourette's)
Who might prefer brexpiprazole
- Aripiprazole-induced akathisia or insomnia was a problem
- Anxiety or "wiredness" on aripiprazole was a problem
- Adjunctive treatment of depression where activation is undesirable
- Agitation in Alzheimer's-related dementia (specific approval)
Switching between partial dopamine agonists is usually well-tolerated when done with a cross-taper. Abrupt switches risk return of symptoms. Always work with a prescriber on the timing.
This article is for educational purposes only and is not medical advice, diagnosis, or treatment. Information is summarised from publicly available FDA labelling and peer-reviewed literature. Always consult your prescribing clinician before starting, stopping, or changing any medication. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.